Glancy Binkow & Goldberg LLP Announces a December 24, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against Catalyst Pharmaceutical Partners, Inc. -- CPRX

        Print
| Source: Glancy Binkow & Goldberg LLP

LOS ANGELES, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of Catalyst Pharmaceutical Partners, Inc. ("Catalyst" or the "Company") (Nasdaq:CPRX) between October 31, 2012 and October 18, 2013, inclusive (the "Class Period'), have until December 24, 2013, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of Florida.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Catalyst is a pharmaceutical company focused on developing and marketing novel prescription drugs targeting rare neuromuscular and neurological diseases and disorders. One of the Company's principal products is Firdapse, currently in Phase III clinical trials for treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disease. The Complaint alleges that defendants failed to disclose that a competitor company has been manufacturing a drug equivalent to Firdapse, and providing it to patients with LEMS, free of charge through a compassionate use program, for the past 20 years. On October 18, 2013, an article published by TheStreet alleged that Catalyst's Firdapse is the same drug that its competitor has been manufacturing and providing in the U.S. for the past 20 years.

To be a member of the Class you need not take any action at this time or may retain counsel of your choice. If you wish to learn more about this action, or if you have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
(888) 773-9224
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
(212) 682-5340

www.glancylaw.com